Serum anti-NMDA-receptor antibodies and cognitive function after ischemic stroke (PROSCIS-B).

Pia Sophie SperberPimrapat GebertLeonie H A BroersenShufan HuoSophie K PiperBianca TeegenPeter U HeuschmannHarald PrüssMatthias EndresThomas G LimanBob Siegerink

Published in: Journal of neurology (2022)

In our study, NMDAR1-abs seropositivity did not affect CF over 3 years after a first mild to moderate ischemic stroke. CF differed according to NMDAR1-abs serum titer, with patients with high NMDAR1-abs titers having a less favorable cognitive outcome compared to seronegative patients.

Keyphrases

cystic fibrosis
end stage renal disease
atrial fibrillation
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis